Ko te Whakaingoatanga Taaru pani hou mo te maimoatanga o te Follicular Lymphoma

tuhituhia e ētita

Ko CASI Pharmaceuticals, Inc., he kamupene biopharmaceutical US e arotahi ana ki te whakawhanake me te hokohoko i nga rongoa hou me nga hua rongoa, i panuitia i tenei ra, kua tukuna e te US Food and Drug Administration (FDA) te Tohu Whakataunga Orphan Drug (ODD) ki tana hoa a BioInvent International AB, mo BI-1206, he anti-FcyRllB antibody whakatewhatewha, mo te maimoatanga o te lymphoma follicular (FL), te ahua tino nui o te puhoi te tipu o te lymphoma Non-Hodgkin (NHL).

Tuku Pai, PDF & Īmēra

Ko BI-1206 te kaitono tarukino matua a BioInvent, a kei te tirotirohia i tenei wa i roto i nga whakamatautau e rua Wāhanga 1/2. Ko tetahi kei te arotake i te huinga BI-1206 me te rituximab mo te maimoatanga o te lymphoma Non-Hodgkin, kei roto ko nga turoro me te FL, MCL me te lymphoma rohe taha (MZL) kua hoki mai, kua kore e kaha ki te rituximab. Ko te whakamatautau tuarua o te Wāhanga 1/2 kei te tirotirohia te BI-1206 me te rongoa anti-PD1 Keytruda® (pembrolizumab) i roto i nga pukupuku totoka.

I korero a Takuta Wei-Wu He, te Tiamana me te Tumuaki o CASI, "Kei te ahu whakamua tonu a BioInvent me te anga whanaketanga me te anga ture mo BI-1206. Ko te whakaaetanga a te CTA i Haina i te Hakihea 2021 me te Whakataunga Taaru Orphan FDA tata nei e whakaatu ana i te kaha kaha o tenei antibody tuatahi-i-akomanga. Kei a CASI nga mana arumoni a Haina o BI-1026, a kei te whakarite ta matou roopu mo te rangahau haumanu a Haina. Ko te CASI me te BioInvent he hoa piripono me te whainga noa ki te whai hua ki nga turoro me nga hangarau rongoa hou.

Tuku Pai, PDF & Īmēra

Mō te kaituhi

ētita

Ko te Kaiwhakahaere Matua mo eTurboNew ko Linda Hohnholz. Kei roto ia i te eTN HQ i Honolulu, Hawaii.

Waiho i te Comment